Hookipa Biotech Gmbh
Clinical trials sponsored by Hookipa Biotech Gmbh, explained in plain language.
-
New HIV immune training shot shows promise in early trial
Disease control TerminatedThis study tested two experimental shots, HB-502 and HB-501, designed to teach the body's immune system to recognize and fight HIV. It involved 30 adults with HIV who were already on stable antiretroviral therapy (ART). The main goal was to check safety and whether the shots coul…
Phase: PHASE1 • Sponsor: Hookipa Biotech GmbH • Aim: Disease control
Last updated May 17, 2026 08:54 UTC
-
Early trial of HPV cancer drug stopped short
Knowledge-focused TerminatedThis very early (Phase 0) trial tested a drug called HB-201 in 10 people with HPV 16+ head and neck or cervical cancer. The goal was to see how the drug affected the immune system, not to treat the cancer directly. The study was terminated early, so results are limited.
Phase: EARLY_PHASE1 • Sponsor: Hookipa Biotech GmbH • Aim: Knowledge-focused
Last updated May 11, 2026 20:54 UTC